Hybrid Nanoparticles for Combination Therapy of Cancer

Overview

Journal J Control Release

Specialty Pharmacology

Date 2015 Sep 22

PMID 26387745

Citations 41

Authors

Chunbai He

Jianqin Lu

Wenbin Lin

Affiliations

Soon will be listed here.

Abstract

Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.

Citing Articles

Herbal based nanoparticles as a possible and potential treatment of cancer: a review.

Yadav R, Chawra H, Dubey G, Alam M, Kumar V, Sharma P Explor Target Antitumor Ther. 2025; 6:1002285.

PMID: 40061135 PMC: 11885881. DOI: 10.37349/etat.2025.1002285.

Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy.

Theivendren P, Kunjiappan S, Pavadai P, Ravi K, Murugavel A, Dayalan A ACS Meas Sci Au. 2025; 5(1):31-55.

PMID: 39991031 PMC: 11843507. DOI: 10.1021/acsmeasuresciau.4c00062.

Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.

Abu Saleem E, Lafi Z, Shalan N, Alshaer W, Hamadneh I Nanomedicine (Lond). 2025; 20(5):467-479.

PMID: 39888613 PMC: 11875491. DOI: 10.1080/17435889.2025.2459059.

Effectiveness of computer-based telerehabilitation software (RehaCom) compared to other treatments for patients with cognitive impairments: A systematic review.

Sarpourian F, Bahaadinbeigy K, Fatemi Aghda S, Fatehi F, Ebrahimi S, Fallahnezhad M Digit Health. 2024; 10:20552076241290957.

PMID: 39600389 PMC: 11590163. DOI: 10.1177/20552076241290957.

Nanomedicine marvels: crafting the future of cancer therapy with innovative statin nano-formulation strategies.

Karimi Jirandehi A, Asgari R, Shahbaz S, Rezaei N Nanoscale Adv. 2024; .

PMID: 39478996 PMC: 11515941. DOI: 10.1039/d4na00808a.

References

Hu M, Chen J, Li Z, Au L, Hartland G, Li X . Gold nanostructures: engineering their plasmonic properties for biomedical applications. Chem Soc Rev. 2006; 35(11):1084-94. DOI: 10.1039/b517615h. View

Castano A, Mroz P, Hamblin M . Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006; 6(7):535-45. PMC: 2933780. DOI: 10.1038/nrc1894. View

Pissuwan D, Niidome T, Cortie M . The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release. 2009; 149(1):65-71. DOI: 10.1016/j.jconrel.2009.12.006. View

Li S, Huang L . Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008; 5(4):496-504. DOI: 10.1021/mp800049w. View

Wang C, Xie Z, Dekrafft K, Lin W . Doping metal-organic frameworks for water oxidation, carbon dioxide reduction, and organic photocatalysis. J Am Chem Soc. 2011; 133(34):13445-54. DOI: 10.1021/ja203564w. View

Gupta A, Gupta M . Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26(18):3995-4021. DOI: 10.1016/j.biomaterials.2004.10.012. View

Wang C, Liu D, Lin W . Metal-organic frameworks as a tunable platform for designing functional molecular materials. J Am Chem Soc. 2013; 135(36):13222-34. PMC: 3800686. DOI: 10.1021/ja308229p. View

Lovell J, Jin C, Huynh E, MacDonald T, Cao W, Zheng G . Enzymatic regioselection for the synthesis and biodegradation of porphysome nanovesicles. Angew Chem Int Ed Engl. 2012; 51(10):2429-33. DOI: 10.1002/anie.201108280. View

Li Z, Huve J, Krampe C, Luppi G, Tsotsalas M, Klingauf J . Internalization pathways of anisotropic disc-shaped zeolite L nanocrystals with different surface properties in HeLa cancer cells. Small. 2013; 9(9-10):1809-20. DOI: 10.1002/smll.201201702. View

10.

Huo Q, Liu J, Wang L, Jiang Y, Lambert T, Fang E . A new class of silica cross-linked micellar core-shell nanoparticles. J Am Chem Soc. 2006; 128(19):6447-53. DOI: 10.1021/ja060367p. View

11.

Della Rocca J, Werner M, Kramer S, Huxford-Phillips R, Sukumar R, Cummings N . Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy. Nanomedicine. 2014; 11(1):31-8. PMC: 4280316. DOI: 10.1016/j.nano.2014.07.004. View

12.

Poon C, He C, Liu D, Lu K, Lin W . Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release. 2015; 201:90-9. PMC: 4624312. DOI: 10.1016/j.jconrel.2015.01.026. View

13.

Ling D, Lee N, Hyeon T . Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc Chem Res. 2015; 48(5):1276-85. DOI: 10.1021/acs.accounts.5b00038. View

14.

Wang Y, Chen J, Yan X . Fabrication of transferrin functionalized gold nanoclusters/graphene oxide nanocomposite for turn-on near-infrared fluorescent bioimaging of cancer cells and small animals. Anal Chem. 2013; 85(4):2529-35. DOI: 10.1021/ac303747t. View

15.

Liu D, Lu K, Poon C, Lin W . Metal-organic frameworks as sensory materials and imaging agents. Inorg Chem. 2013; 53(4):1916-24. PMC: 4108452. DOI: 10.1021/ic402194c. View

16.

He C, Lu K, Liu D, Lin W . Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc. 2014; 136(14):5181-4. PMC: 4210117. DOI: 10.1021/ja4098862. View

17.

Wang X, Chen H, Zheng Y, Ma M, Chen Y, Zhang K . Au-nanoparticle coated mesoporous silica nanocapsule-based multifunctional platform for ultrasound mediated imaging, cytoclasis and tumor ablation. Biomaterials. 2012; 34(8):2057-68. DOI: 10.1016/j.biomaterials.2012.11.044. View

18.

Dekrafft K, Xie Z, Cao G, Tran S, Ma L, Zhou O . Iodinated nanoscale coordination polymers as potential contrast agents for computed tomography. Angew Chem Int Ed Engl. 2009; 48(52):9901-4. DOI: 10.1002/anie.200904958. View

19.

Jensen S, Day E, Ko C, Hurley L, Luciano J, Kouri F . Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med. 2013; 5(209):209ra152. PMC: 4017940. DOI: 10.1126/scitranslmed.3006839. View

20.

Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T . Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol. 2006; 29(4):376-9. DOI: 10.1097/01.coc.0000224494.07907.4e. View